Medline (MDLN) Q1 2026 earnings review
Robust Top-Line Growth Masked by Severe Margin Compression
Medline's Q1 2026 delivered an impressive 10.7% revenue jump, driven by aggressive new customer implementations and existing account growth. Management was confident enough to raise full-year organic growth guidance to 8.5%-9.5%. However, beneath the strong top line, profitability is reversing. Net income plummeted 25.8% and Adjusted EBITDA fell 10.6% as tariffs, implementation costs, and IPO-related bonuses crushed margins. Working capital needs to support this growth also dragged Free Cash Flow down nearly 46%. It is a classic case of paying a heavy price for market share.
🐂 Bull Case
Medline continues to win massive market share. Supply Chain Solutions surged 15% YoY, and organic growth of 10.1% proves the core engine is accelerating despite market uncertainties.
Management confidently raised the full-year 2026 Organic Sales growth target to 8.5%-9.5%, signaling a high visibility into ongoing customer onboarding and implementation success.
🐻 Bear Case
Gross margin contracted by 250 basis points (27.5% to 25.0%). Tariffs and aggressive spending to support new customers mean revenue growth is actively destroying profit margins.
Operating cash flow cratered by almost 40%. The company is tying up significant cash in inventory and receivables to fuel its sales growth, raising questions about the sustainability of this capital-intensive expansion.
⚖️ Verdict: ⚪
Neutral. The sheer scale of top-line growth and market share capture is undeniable. However, the severe margin compression and massive drop in cash flow show the company is essentially buying this growth. Until margins stabilize, the bottom line will continue to suffer.
Key Themes
Supply Chain Solutions is the Growth Engine
The Supply Chain Solutions segment is accelerating rapidly, delivering a massive 15.0% YoY revenue jump to $3.89B. This clearly validates Medline's strategy of aggressively onboarding new enterprise customers and expanding existing accounts. However, this growth came with a slight margin penalty, as Adjusted EBITDA margins dipped from 5.4% to 4.8%.
Tariffs and COGS Decimate Margins
The most glaring red flag in this report is the reversing trajectory of profitability. Cost of Goods Sold spiked 14.3%—vastly outpacing the 10.7% revenue growth. Management explicitly blamed tariffs and the upfront costs of supporting new customers. Consequently, Gross Margin compressed violently from 27.5% in 25Q1 to 25.0% in 26Q1. Pricing power appears severely constrained.
Working Capital Chokes Free Cash Flow
Despite adding $708M in new quarterly sales, Net Cash Provided by Operating Activities collapsed by 39.6% to $412M. This contradicts the positive growth narrative. The culprit: massive working capital builds. Medline is tying up cash in soaring Accounts Receivable (up to $3.67B) and swollen Inventories ($4.81B) just to fulfill its new contracts. Growth is getting expensive.
Automation and Infrastructure Investments
Medline maintained strong CapEx spending ($96M in Q1) specifically targeted at automation within its distribution centers and kitting manufacturing facilities. While this drags on near-term Free Cash Flow, it is the exact structural remedy needed to offset the surging labor and operational costs currently pressuring margins.
Core Brand Profitability is Slipping
While Supply Chain Solutions is a low-margin business by nature, the Medline Brand segment is the historical profit engine. Troublingly, Medline Brand Adjusted EBITDA outright declined by 7.8% to $765M, and its margin shrank significantly from 25.4% to 22.1%. If the proprietary brand cannot hold its pricing power against macro tariff impacts, the overall EBITDA guidance is at serious risk.
Other KPIs
Decelerating violently. Dropped 250 basis points YoY from 27.5% in Q1 2025. This proves that while Medline can win the volume game, they are currently absorbing the blow from global tariffs rather than passing those costs onto their healthcare clients.
Stable. Total debt stands at $12.7B against $2.2B in cash, yielding net debt of $10.5B. Following the 2025 IPO and debt refinancing, this leverage ratio has improved dramatically from the 4.9x seen at the end of 2024, providing a solid balance sheet cushion despite the current cash flow crunch.
Accelerating. Rose 14.8% YoY, outstripping the 10.7% revenue growth. The primary drivers were staffing investments to handle new customer implementations and one-time IPO-related employee bonuses.
Guidance
Accelerating vs prior guidance. Raised from the previous outlook of 8% to 9%. With Q1 already delivering 10.1% organic growth, this guidance suggests management expects strong, albeit slightly moderating, implementation momentum through the rest of the year.
Stable. The company maintained this range. Achieving the $3.55B midpoint requires roughly 2.4% YoY growth from FY25's $3.467B. Given the 10.6% drop in Q1 EBITDA, management is heavily implicitly guiding for a sharp margin recovery or massive operational leverage in H2 2026 to hit this target.
Key Questions
Tariff Mitigation Timeline
You specifically called out tariffs dragging down Gross Margins to 25.0%. What is the precise timeline and mechanism (pricing vs alternative sourcing) for recovering these lost margin points in the back half of the year?
Working Capital Normalization
Operating cash flow dropped nearly 40% due to Accounts Receivable and Inventory builds for new customers. When do you expect working capital requirements for these new cohorts to normalize and start contributing positively to Free Cash Flow?
Bridge to EBITDA Guidance
With Q1 Adjusted EBITDA down 10.6% YoY, maintaining the $3.5-$3.6B full-year guidance requires a massive inflection in profitability. What specific cost levers or pricing actions give you confidence in this back-half acceleration?